Semax (10mg) – SX10

Semax (10mg) — Research Peptide

Semax at 10mg per vial offers a higher-dose format of this ACTH-derived nootropic heptapeptide for extended research protocols. Semax has an established clinical research record in Russia and Eastern Europe, with registered pharmaceutical formulations and published controlled trials in neurological conditions — providing a research foundation that distinguishes it from many investigational peptides.

Neurotrophin and Neuroprotection Research

The most extensively published aspect of Semax biology is its upregulation of BDNF and associated neurotrophin signalling. Research by Dolotov et al. and Levitskaya et al. documented dose-dependent BDNF mRNA and protein increases in rat hippocampal and cortical tissue following Semax administration. Given BDNF’s central role in long-term potentiation, synaptic plasticity, and neuronal survival, these findings have positioned Semax as a research tool in neuroplasticity and neuroprotection models.

Neuroprotection studies in ischaemic models have shown Semax reduces infarct volume and neurological deficit scores in MCAO (middle cerebral artery occlusion) rat models — findings consistent with its clinical investigation in ischaemic stroke. These results are attributed to both its neurotrophin-upregulating effects and documented anti-inflammatory actions in CNS tissue.

Product Specifications

• Peptide: Semax (ACTH(4-7)-Pro-Gly-Pro)
• Dose: 10mg per vial
• Format: Lyophilised powder, bulk box of 10 vials
• Purity: ≥98% Janoshik HPLC verified
• Storage: -20°C. 24-month stability.

For laboratory research use only. Not for human therapeutic use.